1. Home
  2. CNXU vs OBIO Comparison

CNXU vs OBIO Comparison

Compare CNXU & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Conexeu Sciences Inc. Common Stock

CNXU

Conexeu Sciences Inc. Common Stock

N/A

Current Price

$7.76

Market Cap

208.4M

Sector

Health Care

ML Signal

N/A

Logo Orchestra BioMed Holdings Inc.

OBIO

Orchestra BioMed Holdings Inc.

HOLD

Current Price

$4.12

Market Cap

238.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNXU
OBIO
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
208.4M
238.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CNXU
OBIO
Price
$7.76
$4.12
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.25
AVG Volume (30 Days)
134.1K
196.7K
Earning Date
N/A
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.13
EPS
N/A
N/A
Revenue
N/A
$33,482,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1169.22
52 Week Low
$7.10
$2.20
52 Week High
$13.66
$5.42

Technical Indicators

Market Signals
Indicator
CNXU
OBIO
Relative Strength Index (RSI) 36.73 59.34
Support Level $7.62 $4.07
Resistance Level $11.51 $4.18
Average True Range (ATR) 1.25 0.16
MACD -0.08 0.05
Stochastic Oscillator 9.91 96.49

Price Performance

Historical Comparison
CNXU
OBIO

About CNXU Conexeu Sciences Inc. Common Stock

Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

Share on Social Networks: